Make an enquiry
Refer a patient
Patient Portal
We noticed you are on our AU page. Want to switch regions? Choose from the options:
US
UK
ES
Find a centre
Find a doctor
Make an enquiry
Refer a patient
Patient Portal
We noticed you are on our AU page. Want to switch regions? Choose from the options:
US
UK
ES
Find a centre
Find a doctor
Make an enquiry
Refer a patient
Patient Portal
Healthcare Professionals
Research and insights
Publications
Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer
22 Nov 2018
Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer
Written by
Heck M; Tauber R; Schwaiger S et al.;
Back to top